Bulletin 130: Biosimilars - Insulin analogues
Biosimilar insulin glargine is the most recent biosimilar to become available within the NHS. This product will be of particular interest in primary care as there is significant primary care prescribing of the insulin analogues. Primary care commissioners/Pharmacy Leads need to be able to understand the particular issues that relate to the biosimilar version of insulin glargine as well as the key issues affecting uptake.
